UNSPSC 51203103: Thymocartin

This classification denotes a therapeutic hormone with the molecular formula C21H40N8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) M0H0SK3AD5, chemically known as l-valine, n-(n-(n(sup 2)-l-arginyl-l-lysyl)-l-alpha-aspartyl)- but more generally known as thymocartin, which bears US NIH Compound Identifier 3033954. European Medicines Agency schedules Thymocartin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10991MIG.

UNSPSC 51203103 Thymocartin, a Commodity code, does not align with recent state and local procurement activity. The four most recent opportunities tagged with or near this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic pharmaceuticals and over-the-counter products distributed through cooperative purchasing — none of which center on thymocartin specifically. The mismatch suggests either inconsistent code assignment in source systems or that thymocartin procurement, if it occurs at the state and local level, is not currently surfacing in active solicitations.

The opportunities that do appear under or adjacent to this code span multiple issuing-body types and geographies. Seminole County, Florida issued an IFB (IFB60459723LAS) due July 26, 2023, for naloxone and drug deactivation systems; the City of Tampa released an IFB (26P00145) with a March 13, 2026 due date for medical and first aid supplies supporting the Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a 5% small local business enterprise discount cap; the Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products serving state, local, and participating out-of-state facilities including Oregon. Activity spans Florida, Texas, and Minnesota, with cooperative purchasing mechanisms appearing alongside traditional county and municipal procurements. No active solicitations specifically naming thymocartin were identified.